FDA approves first nasal spray flu vaccine for use at home
The Food and Drug Administration on Friday approved the first at-home flu vaccine, a nasal spray that consumers with a ...
FDA approves first self-administered flu vaccine spray
The Food and Drug Administration announced Friday it had broadened the approval of the FluMist nasal spray to become the ...
Nasal Flu Vaccine Is Approved for At-Home Use
The F.D.A. authorized AstraZeneca’s treatment to be given outside a health care setting, although it will still need a ...
FDA approves first flu vaccine that can be self-administered at home
The US Food and Drug Administration on Friday approved the first flu vaccine that does not have to be administered by a ...
US FDA approves AstraZeneca's self-administered nasal spray flu vaccine
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...
US FDA approves AstraZeneca's flu vaccine for self-administration
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for ...
FDA approves first self-administered flu vaccine
The Food and Drug Administration (FDA) announced Friday it has approved the first flu vaccine that can be self-administered, ...
Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line
Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...
AstraZeneca falls Friday, still outperforms market
AstraZeneca PLC AZN shares inched down 0.99% to £117.80 Friday, on what proved to be an all-around rough trading session for ...
FiercePharma4h
With FDA nod, AstraZeneca's FluMist becomes first self-administered flu vaccine
AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on ...
AstraZeneca India to launch Palivizumab in Oct 2024, stocks trade flat
AstraZeneca Pharma India to launch Palivizumab in India, a drug to prevent RSV in high-risk children. Stocks rise.
AstraZeneca: Poised for Growth with Promising Innovation Pipeline and Attractive Valuation
In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on AstraZeneca (AZN – Research Report), with a ...